Hyperacidity, GERD, and ulcers:
Indications for: PEPCID SUSPENSION
In adults with: active duodenal ulcer; reduction of the risk duodenal ulcer recurrence; active gastric ulcer; symptomatic nonerosive gastroesophageal reflux disease (GERD); erosive esophagitis (EE); pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas). In children aged ≥1 year: peptic ulcer disease; GERD with or without esophagitis and ulcerations. In newborns to <1yr: GERD.
Duodenal ulcer: 40mg once daily at bedtime or 20mg twice daily for up to 8 weeks. Recurrence: 20mg once daily at bedtime for up to 1 year or as clinically indicated. Gastric ulcer: 40mg once daily at bedtime for up to 8 weeks. GERD: 20mg twice daily for up to 6 weeks. EE: 20mg or 40mg twice daily for up to 12 weeks. Hypersecretory conditions: initially 20mg every 6hrs; individualize; max 160mg every 6hrs. Renal impairment: see full labeling.
Peptic ulcer: <1yr: not established. 1–16yrs: initially 0.5mg/kg/day at bedtime or 0.25mg/kg twice daily; may increase to 1mg/kg/day or 0.5mg/kg twice daily; max 40mg/day. Treat for 8 weeks. GERD: Birth–<3mos: initially 0.5mg/kg/day; may increase to 1mg/kg/day. 3mos–<1yr: initially 0.5mg/kg twice daily; may increase to 1mg/kg twice daily; max 40mg/day. 1–16yrs: 0.5mg/kg twice daily; max 40mg twice daily. Treat for up to 8 weeks (birth–<1yr) or up to 6–12 weeks (1–16yrs).
PEPCID SUSPENSION Contraindications:
History of serious hypersensitivity reactions to H2 receptor antagonists.
PEPCID SUSPENSION Warnings/Precautions:
Symptomatic response does not preclude gastric malignancy; evaluate prior to initiation. Moderate to severe renal impairment (CrCl <50mL/min): reduce to ½ the dose or prolong dosing interval to 36–48hrs. Elderly: use low doses. Pregnancy. Nursing mothers.
PEPCID SUSPENSION Classification:
PEPCID SUSPENSION Interactions:
Concomitant dasatinib, delavirdine mesylate, cefditoren, fosamprenavir: not recommended. May alter absorption of pH-dependent drugs (eg, atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, rilpivirine). May potentiate CYP1A2 substrates (eg, tizanidine); avoid; if necessary, monitor for hypotension, bradycardia, drowsiness. May give antacids concomitantly.
Headache, dizziness, constipation, diarrhea, inj site reactions; rare: CNS reactions, prolonged QT interval in renal impairment (moderate and severe).
Tabs—30, 100; Susp—50mL; Inj—contact supplier